Exjade

DRUG5 trials

Conditions

Increased Iron Storage / Disturbed DistributionMyelodysplastic SyndromeMyelodysplastic SyndromesMyeloid LeukemiaNon-alcoholic SteatohepatitisPorphyria Cutanea TardaThalassemia Major

Phase 1

The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis

CompletedNCT01278056

Crolll GmbhIncreased Iron Storage / Disturbed Distribution, Non-alcoholic Steatohepatitis

Start: 2010-03-31End: 2012-07-31Updated: 2012-07-20

Phase 2

Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda

NCT01284946

Assistance Publique - Hôpitaux de ParisPorphyria Cutanea Tarda

Start: 2011-01-31End: 2012-12-31Target: 45Updated: 2011-01-27

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

CompletedNCT03637556

DisperSol Technologies, LLCThalassemia Major

Start: 2019-08-20End: 2021-08-16Updated: 2022-02-01

Phase 4

Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load

CompletedNCT00452660

Wolfson Medical CenterMyelodysplastic Syndrome

Start: 2007-05-31End: 2008-08-31Updated: 2014-06-16

Unknown Phase

Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

NCT03659084

Hospices Civils de LyonMyelodysplastic Syndromes, Myeloid Leukemia

Start: 2016-04-30End: 2020-04-30Target: 150Updated: 2018-09-06

Exjade

Sponsors

Conditions

Phase 1

Phase 2

Phase 4

Unknown Phase